Limits...
Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.

Kwon YS, Nam JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT - J. Korean Med. Sci. (2009)

Bottom Line: Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment.For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235).No treatment-related adverse events were reported during the follow-up period.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.

ABSTRACT
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.

Show MeSH

Related in: MedlinePlus

Progression-free survival of HMM-treated and -untreated patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2719200&req=5

Figure 1: Progression-free survival of HMM-treated and -untreated patients.

Mentions: Although the median PFS of the HMM-treated group (38 months; 95% confidence interval [CI] 16-60 months) was longer than that of the untreated group (21 months; 95% CI 16-26 months), the difference was not significant (P=0.235) (Fig. 1).


Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.

Kwon YS, Nam JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT - J. Korean Med. Sci. (2009)

Progression-free survival of HMM-treated and -untreated patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2719200&req=5

Figure 1: Progression-free survival of HMM-treated and -untreated patients.
Mentions: Although the median PFS of the HMM-treated group (38 months; 95% confidence interval [CI] 16-60 months) was longer than that of the untreated group (21 months; 95% CI 16-26 months), the difference was not significant (P=0.235) (Fig. 1).

Bottom Line: Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment.For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235).No treatment-related adverse events were reported during the follow-up period.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.

ABSTRACT
The aim of this study was to assess the efficacy of consolidation therapy with hexamethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC). Patients treated at our hospital between January 1997 and November 2006 and in documented clinical complete response from advanced ovarian cancer following front-line platinum-based therapy were retrospectively analyzed. The patients treated with HMM were compared to the patients of matched counterpart without consolidation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received no consolidation treatment. For patients with HMM and observed patients, the mean age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the optimal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free survival were 38 months and 21 months for patients with HMM and observed patients (P=0.235). No treatment-related adverse events were reported during the follow-up period. Although this study failed to show the significant survival benefit of consolidation therapy with HMM in patients with advanced EOC, we consider that our study can contribute data to investigate the effectiveness of consolidation therapy in epithelial ovarian cancer.

Show MeSH
Related in: MedlinePlus